All products / DC10628
Senexin A
Pack sizes and prices
| Pack size | Price |
|---|---|
| 100 mg | $650 USDRequest a quote / confirm availability → |
| 250 mg | $1,300 USDRequest a quote / confirm availability → |
| 1 g | $2,600 USDRequest a quote / confirm availability → |
Confirm stock, lead time, shipping and final quotation with our team.
Product overview
In vitro: p21 is shown to activate NF-κB–dependent transcription, and Senexin A inhibits p21-stimulated activity of the consensus NF-κB–dependent promoter. Senexin A has no effect on p21 induction by IPTG, on cell growth with or without p21, or on p21-induced senescent phenotype. Senexin A does not affect the inhibition of gene expression by p21 and does not interfere with p21-mediated inhibition of large sets of genes belonging to Gene Ontology (GO) categories of mitosis and DNA replication. Senexin A inhibits only p21-induced transcription but not other biological effects of p21. Senexin A inhibits CDK8 and CDK19 ATP site binding with Kd50 of 0.83 μM and 0.31 μM, respectively and CDK8 kinase activity with IC50 of 0.28 μM. Senexin A inhibits β-catenin–dependent transcription in HCT116 colon carcinoma cells. It does not inhibit ROCK and did not share cortistatin A's strong antiendothelial cell activity. In vivo: The CDK8/19 inhibitor Senexin A reverses chemotherapy-induced paracrine tumor-promoting activities in vivo and does not inhibit reporter cell growth and showed no detectable toxicity in a mouse study.
For research use only. Results depend on experimental conditions and do not constitute a performance guarantee.
Identity and specifications
| Catalog number | DC10628 |
|---|---|
| Product name | Senexin A |
| CAS | 1366002-50-7 |
| Molecular formula | C17H14N4 |
| Molecular weight | 274.32 |
| Purity | >98% |
| SMILES | N#Cc1ccc2ncnc(NCCc3ccccc3)c2c1 |
Source-listed specifications; the batch COA applies.
Source and product documents
The supplier source is linked below. Contact us for COA, SDS and batch-specific documents.
DC Chemicals — Senexin A (DC10628)